Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05031663 · ClinicalTrials.gov registry record · NA

Effect of Almonds on Immune Strength and Response to Flu Vaccination in Overweight Older Men and Postmenopausal Women: A Randomized Controlled Study

A NA study of Inflammation and Immune Response, sponsored by Loma Linda University.

Completed
Registry status
NA
Development phase
61
Enrollment target
1
Study location

NCT05031663: Completed NA study of Inflammation and Immune Response, sponsored by Loma Linda University.

NCT05031663 is a NA study of Inflammation and Immune Response that has completed, run by Loma Linda University. The registered enrollment target is 61 participants, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05031663, a NA study of Inflammation and Immune Response, has completed, sponsored by Loma Linda University.

COMPLETED
Registry status
NA
Development phase
61 participants
Enrollment target
1
Study location

Study Summary

This research study will test the effects of almonds on immune functions and immune response to influenza vaccine in overweight middle-aged men and postmenopausal women

Primary Outcome

Immunophenotyping will be performed by flow cytometry to measure the number of T helper, T cytotoxic, Naïve and memory cells and B cells

Conditions Studied

Inflammation Immune Response

Interventions

  • DIETARY_SUPPLEMENT Almond group
  • DIETARY_SUPPLEMENT Control Group

Study Locations (1)

California

  • Loma Linda University School of Public Health - Loma Linda

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2021-08-12
Est. Completion 2023-05-10
Phase NA
Loma Linda University

237 total trials

What the finished NCT05031663 record still lists

NCT05031663 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (79% lower).

The record links to 2 conditions, with Inflammation appearing as the primary indexed condition, and to 2 interventions - of which Almond group is the first listed.

NCT05031663 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05031663 about?

NCT05031663 is a clinical study titled "Effect of Almonds on Immune Strength and Response to Flu Vaccination in Overweight Older Men and Postmenopausal Women: A Randomized Controlled Study". This research study will test the effects of almonds on immune functions and immune response to influenza vaccine in overweight middle-aged men and postmenopausal women

What is the current status of trial NCT05031663?

This trial is currently completed. It is a NA study. The enrollment target is 61 participants. The study started on 2021-08-12. Estimated completion is 2023-05-10.

What conditions does trial NCT05031663 study?

This clinical trial studies the following conditions: Inflammation, Immune Response.

What interventions are being tested in trial NCT05031663?

The interventions under investigation include: Almond group (DIETARY_SUPPLEMENT), Control Group (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05031663?

This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05031663 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Inflammation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05031663's enrollment target sits among peer trials

61 68th of 132 higher than 65 of 132 other Inflammation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Inflammation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04115306 · 61 participants · Phase 1

    Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

  • NCT05070845 · 61 participants · Phase 2

    Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

  • NCT05187832 · 61 participants · Phase 1

    A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

  • NCT05269316 · 61 participants · Phase 1

    Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05031663, the US trial registry maintained by the National Library of Medicine. NCT05031663 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.